PARP inhibitors coming of age

Affiliations

¹ Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
² Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. fatimacardoso@fundacaochampalimaud.pt.

Comment

Shani Paluch-Shimon et al. Nat Rev Clin Oncol. 2021 Feb.

. 2021 Feb;18(2):69-70.

doi: 10.1038/s41571-020-00452-2.

¹ Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
² Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. fatimacardoso@fundacaochampalimaud.pt.

No abstract available

Comment on

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Litton JK, et al. Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20. Ann Oncol. 2020. PMID: 32828825 Free PMC article. Clinical Trial.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Diéras V, et al. Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27. Lancet Oncol. 2020. PMID: 32861273 Clinical Trial.

1. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005). - DOI
1. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). - DOI
1. Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA tutation. N. Engl. J. Med. 377, 523–533 (2017). - DOI
1. Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558–566 (2019). - DOI
1. Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018). - DOI